A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

September 12, 2019

Study Completion Date

April 9, 2020

Conditions
Myopia
Interventions
DRUG

DE-127 Ophthalmic Solution low dose

Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

DRUG

DE-127 Ophthalmic Solution medium dose

Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

DRUG

DE-127 Ophthalmic Solution high dose

High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months

DRUG

Placebo Ophthalmic Solution

Placebo Ophthalmic Solution dosed once daily for 12 months

Trial Locations (1)

Unknown

Singapore National Eye Centre, Singapore

All Listed Sponsors
lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT03329638 - A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE) | Biotech Hunter | Biotech Hunter